PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Sold by Diversified Trust Co

Diversified Trust Co reduced its holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 27.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,649 shares of the company’s stock after selling 1,775 shares during the period. Diversified Trust Co’s holdings in PROCEPT BioRobotics were worth $374,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Lord Abbett & CO. LLC boosted its stake in shares of PROCEPT BioRobotics by 45.3% in the third quarter. Lord Abbett & CO. LLC now owns 748,555 shares of the company’s stock worth $59,974,000 after acquiring an additional 233,430 shares during the last quarter. Federated Hermes Inc. boosted its stake in shares of PROCEPT BioRobotics by 788.9% in the second quarter. Federated Hermes Inc. now owns 183,420 shares of the company’s stock worth $11,205,000 after acquiring an additional 162,785 shares during the last quarter. Penserra Capital Management LLC acquired a new stake in shares of PROCEPT BioRobotics in the third quarter worth approximately $2,308,000. Principal Financial Group Inc. boosted its stake in shares of PROCEPT BioRobotics by 290.2% in the third quarter. Principal Financial Group Inc. now owns 68,617 shares of the company’s stock worth $5,498,000 after acquiring an additional 51,030 shares during the last quarter. Finally, EP Wealth Advisors LLC acquired a new stake in shares of PROCEPT BioRobotics in the third quarter worth approximately $1,158,000. 89.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at PROCEPT BioRobotics

In related news, EVP Alaleh Nouri sold 28,092 shares of the stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $97.13, for a total transaction of $2,728,575.96. Following the transaction, the executive vice president now owns 52,472 shares of the company’s stock, valued at approximately $5,096,605.36. This represents a 34.87 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Reza Zadno sold 26,420 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $97.83, for a total value of $2,584,668.60. Following the transaction, the chief executive officer now directly owns 179,185 shares in the company, valued at approximately $17,529,668.55. The trade was a 12.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 487,816 shares of company stock worth $44,820,549 over the last quarter. 17.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Wells Fargo & Company reiterated an “overweight” rating and set a $112.00 price objective on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Morgan Stanley assumed coverage on PROCEPT BioRobotics in a research report on Monday, December 2nd. They set an “overweight” rating and a $105.00 price objective on the stock. Jefferies Financial Group assumed coverage on PROCEPT BioRobotics in a research report on Thursday, November 14th. They set a “hold” rating and a $95.00 price objective on the stock. Truist Financial reiterated a “buy” rating and set a $105.00 price objective (up previously from $95.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, October 30th. Finally, TD Cowen lifted their price objective on PROCEPT BioRobotics from $75.00 to $99.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, PROCEPT BioRobotics has an average rating of “Moderate Buy” and an average target price of $97.86.

PROCEPT BioRobotics Price Performance

NASDAQ:PRCT opened at $86.85 on Friday. PROCEPT BioRobotics Co. has a 52 week low of $44.02 and a 52 week high of $103.81. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $4.53 billion, a P/E ratio of -44.54 and a beta of 1.05. The stock’s fifty day moving average is $90.28 and its two-hundred day moving average is $78.19.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its earnings results on Monday, October 28th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.09. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The company had revenue of $58.40 million for the quarter, compared to the consensus estimate of $53.30 million. During the same quarter in the previous year, the business earned ($0.51) earnings per share. The company’s revenue for the quarter was up 66.4% on a year-over-year basis. Equities analysts expect that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).